Standout Papers

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer 2014 2026 2018 2022 1.8k
  1. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer (2014)
    Thomas Powles, Joseph P. Eder et al. Nature
  2. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma (2021)
    Thomas Powles, Jonathan E. Rosenberg et al. New England Journal of Medicine
  3. TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors (2021)
    Scott T. Tagawa, Arjun Vasant Balar et al. Journal of Clinical Oncology
  4. Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up (2021)
    Tom Powles, Joaquim Bellmunt et al. Annals of Oncology
  5. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial (2021)
    Evan Y. Yu, Daniel P. Petrylak et al. The Lancet Oncology
  6. Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma (2023)
    Yohann Loriot, Nobuaki Matsubara et al. New England Journal of Medicine
  7. Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up (2023)
    Thomas Powles, Se Hoon Park et al. Journal of Clinical Oncology
  8. EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma (2023)
    Jonathan E. Rosenberg, Thomas Powles et al. Annals of Oncology
  9. ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma (2024)
    Thomas Powles, Joaquim Bellmunt et al. Annals of Oncology

Immediate Impact

18 by Nobel laureates 8 from Science/Nature 75 standout
Sub-graph 1 of 19

Citing Papers

Prostate Cancer
2025 Standout
Current best practice for bladder cancer: a narrative review of diagnostics and treatments
2022 Standout
16 intermediate papers

Works of Yohann Loriot being referenced

Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma
2021 Standout
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
2014 StandoutNature
and 14 more

Author Peers

Author Last Decade Papers Cites
Yohann Loriot 4140 5998 4383 451 11.3k
Guru Sonpavde 6237 6652 4949 621 14.5k
Noah M. Hahn 5493 4349 4403 260 11.0k
Matthew D. Galsky 6226 5467 3730 384 12.7k
Jonathan E. Rosenberg 6703 5387 4043 399 13.0k
Elizabeth R. Plimack 5664 7764 6099 315 13.6k
Ulka N. Vaishampayan 2718 5592 7118 490 12.5k
Ugo De Giorgi 2067 3702 4478 482 8.7k
Christophe Massard 1199 6877 5908 426 12.3k
Bhumsuk Keam 1349 5905 3935 367 9.6k
Thomas Powles 5003 5758 2754 333 10.0k

All Works

Loading papers...

Rankless by CCL
2026